tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Bristol Myers (BMY) and Kodiak Sciences (KOD)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Eli Lilly & Co (LLYResearch Report), Bristol Myers (BMYResearch Report) and Kodiak Sciences (KODResearch Report) with bullish sentiments.

Eli Lilly & Co (LLY)

In a report issued on May 13, Kerry Holford from Berenberg Bank maintained a Buy rating on Eli Lilly & Co, with a price target of $345.00. The company’s shares closed last Friday at $291.63.

Holford has an average return of 12.3% when recommending Eli Lilly & Co.

According to TipRanks.com, Holford is ranked #1765 out of 7881 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eli Lilly & Co with a $321.07 average price target, representing a 9.7% upside. In a report issued on April 29, Truist Financial also maintained a Buy rating on the stock with a $342.00 price target.

See the top stocks recommended by analysts >>

Bristol Myers (BMY)

In a report issued on May 13, Luisa Hector from Berenberg Bank maintained a Buy rating on Bristol Myers, with a price target of $82.00. The company’s shares closed last Friday at $75.80, close to its 52-week high of $78.17.

According to TipRanks.com, Hector is a 4-star analyst with an average return of 13.3% and a 85.2% success rate. Hector covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Merck & Company, and Sanofi.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $76.30 average price target, representing a -0.2% downside. In a report issued on May 2, Truist Financial also maintained a Buy rating on the stock with a $81.00 price target.

Kodiak Sciences (KOD)

In a report issued on May 14, Anita Dushyanth from Berenberg Bank maintained a Buy rating on Kodiak Sciences, with a price target of $24.00. The company’s shares closed last Friday at $5.53, close to its 52-week low of $4.90.

According to TipRanks.com, Dushyanth is ranked 0 out of 5 stars with an average return of -35.1% and a 18.5% success rate. Dushyanth covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Bioxcel Therapeutics, and Sera Prognostics.

Currently, the analyst consensus on Kodiak Sciences is a Moderate Buy with an average price target of $18.89.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LLY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed